Compare Lithium Americas Corp (LAC) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lithium Americas Corp vs Viatris Inc — how do they compare? Lithium Americas Corp trades at $3.07 (market cap $1.01B), while Viatris Inc trades at $17.54 (market cap $19.79B). The key difference: Viatris Inc is far larger — about 19.6× Lithium Americas Corp's market cap, and Viatris Inc pays a 2.83% dividend while Lithium Americas Corp pays none. Which is the better fit depends on your goals.
| LAC | VTRS | |
|---|---|---|
Market Cap | $1.01B | $19.79B |
Sector | Basic Materials | Health |
52-Week High | $10.05 | $17.39 |
52-Week Low | $2.55 | $8.74 |
Enterprise Value | $1.13B | $32.00B |
Dividend Yield | — | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lithium Americas (LAC) trades at $2.90, down 1.69% on the day, with a bearish technical signal but bullish oscillators. The company reported a net loss of $122.09 million for 2025, with negative ROE and ROA, though it beat EPS estimates in two of the last three quarters. Recent news highlights progress at the Thacker Pass project and potential government support for rare earth minerals, but oversupply concerns weigh on the sector.
The outlook is mixed: analyst consensus leans slightly bullish with no sell ratings, but high cash burn and capital needs pose significant risks. Investment opportunity hinges on successful project execution and lithium demand recovery, while key risks include funding dilution, operational delays, and commodity price volatility.
Viatris (VTRS) trades at $17.59, up 1.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a PDUFA date set for December 2026. Cash flow from operations remains strong at $2.32B, supporting debt reduction efforts.
The outlook is mixed: analyst consensus targets $20.00 (13.7% upside), but profitability challenges and high debt levels pose risks. Investment appeal hinges on successful pipeline execution and margin recovery, while competitive and regulatory pressures in the generics market remain key watchpoints for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Lithium Americas Corp
Lithium Americas is a resource company focused on developing the Thacker Pass project in Nevada, the largest known lithium resource in the US. It aims to become a major supplier for the electric vehicle battery market.
Read more on LAC →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
